RetinalGenix Technologies Inc. (RTGN)
RetinalGenix Technologies Inc.
1450 North Mcdowell Boulevard
Suite 150
Petaluma, CA 94954
United States
415 578 9583
https://retinalgenix.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jerry Katzman | CEO, President & Chairman | N/D | N/D | 1953 |
| Mr. Virender K. Ahluwalia | Interim Chief Financial Officer | N/D | N/D | 1958 |
Descripción
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. Its products include the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
Gestión corporativa
La calificación ISS Governance QuickScore de RetinalGenix Technologies Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
